Direct answer. Exomphalos, also called omphalocele, is a congenital abdominal-wall defect in which bowel and sometimes other organs remain outside the abdomen within a sac. Care assesses associated conditions and plans protection, nutrition and repair. NHS England parent guide Confidence is high in this distinction. Individual prognosis and comparative treatment or supplement benefits are not independently established by this selected educational review.
- Exomphalos and omphalocele are two names for the same condition.
- The covering sac, its contents and other identified conditions matter to the care plan.
- A delayed closure pathway can be an intentional specialist plan; it does not mean that care has been abandoned.
- Repair, breathing support, nutrition and genetic assessment answer separate clinical questions.
Table of contents
- Evidence summary
- What exomphalos or omphalocele is
- Development and associated genetic or heart findings
- Antenatal screening and confirmation
- Genetic testing and fetal heart assessment
- Birth planning and immediate specialist care
- Single, staged and delayed closure pathways
- Breathing support, nutrition and feeding milestones
- Recovery, later hernia and new symptoms
- Urgent illness and dehydration warnings
- Medicines, supplements and research limits
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.
| Claim / intervention | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Diagnosis and associated findings | National/provider clinical education and genomics context | Institutional public/provider routes; author/page and supporting-study interests unclosed. | Explains assessment; no personal genetic, delivery or prognosis rule. |
| Single, staged or delayed closure | Selected clinical options and dated provider care | Source-study funding and comparative technique outcomes not independently verified. | Different pathways require individual surgical assessment; no procedure ranking. |
| Nutrition and nonprescription products | Care descriptions plus generic safety education | Full product/trial financial chain unclosed; no efficacy verdict. | No home nutrition regimen or supplement replacement of specialist care. |
What exomphalos or omphalocele is
In omphalocele, abdominal organs protrude at the umbilicus within a membrane. Gastroschisis lacks this covering sac. Cleveland Clinic anatomical context.
Ask the specialist to show the opening, sac and organs on a diagram. A photograph cannot establish which organs are involved or how much room is available within the abdomen. This condition is distinct from an ordinary umbilical hernia and from exposed bowel in gastroschisis. Using the correct name helps the maternity, neonatal and surgical teams discuss the same diagnosis. “Minor,” “major” and “giant” are descriptive labels, but the team should explain the actual anatomy rather than relying on a size word. This guide does not turn a measurement into an automatic operation decision.
Development and associated genetic or heart findings
GeNotes describes failure of the abdominal wall to develop fully and possible associations with trisomy 13, trisomy 18 and Beckwith–Wiedemann syndrome. These associations do not establish a genetic diagnosis in every baby. GeNotes selected associations.
Ask which additional findings have actually been identified and which are still being investigated. Keep a suspected association separate from a confirmed test result. A broad syndrome label should not be assigned solely from the abdominal-wall appearance. Questions about why this happened deserve a careful clinical explanation; this review does not establish a causal attribution to a parent’s medicine, food or behaviour. Nor does it turn an association into evidence that a supplement would have prevented the defect. The family’s plan should reflect the findings in this pregnancy, not a general list of possible abnormalities.
Antenatal screening and confirmation
The NHS anomaly scan includes exomphalos among screened conditions. Screening does not find every abnormality, and a suspected finding can prompt specialist investigations. NHS screening explanation.
Ask what the initial scan suggests, what the specialist scan has confirmed and which questions remain open. The report should identify the actual anatomy rather than just repeating “abdominal-wall defect.” Request an explanation of the purpose of each later appointment. Is it intended to clarify the diagnosis, look for another finding, or prepare the birth plan? These are different questions. A reassuring result for one investigation does not automatically answer all of them. Keep the written reports available when care moves between hospitals, and ask who coordinates the information so that a pending result is not mistaken for a negative one.
Genetic testing and fetal heart assessment
GeNotes notes that early normal bowel herniation affects scan interpretation and that CVS or amniocentesis may facilitate genetic testing. Cleveland Clinic describes fetal echocardiography to assess associated heart abnormalities. GeNotes diagnostic principles; Cleveland Clinic heart assessment.
Discuss the purpose, limitations and risks of any proposed test with the responsible specialist. Ask what a positive, negative or uncertain result would change, and whether the test examines the particular concern raised by the scan. Genetic counselling should address the actual diagnosis and family circumstances. This article does not provide a universal recurrence percentage or a personal recommendation for invasive testing. If a syndrome is confirmed, ask for its own care explanation; the abdominal-wall guide alone cannot describe every implication. A scan, a chromosome result and a molecular result are different records, and families can ask how the team interprets them together.
Birth planning and immediate specialist care
NHS England describes a team involving neonatologists and paediatric surgeons, with the birth and care plan discussed by the specialist service. NHS England care planning.
Ask where neonatal and surgical support will be available, how transfer would work if required, and whom to contact if labour starts unexpectedly. Timing and mode of delivery require an obstetric assessment; this guide supplies no gestational-age rule or sac-content threshold. After birth, ask who protects and evaluates the sac and who makes the next treatment decision. Families should not push contents inward, open or manipulate the sac, improvise dressings or adjust medical equipment using an article. Request an explanation of the planned stabilization steps and how staff will communicate an unexpected change. The operative discussion should also account for any separately identified heart, lung or genetic condition.
Single, staged and delayed closure pathways
The parent guide describes single repair for a suitable small defect, staged treatment using a silo, or special dressings that allow skin to cover a large sac before later muscle closure. NHS England repair options.
Ask which pathway is proposed and why it fits the baby’s actual condition. A plan to wait for skin coverage is different from immediate closure or progressive reduction in a silo. Request a plain explanation of what remains unclosed, what is protected, and which later operation may still be needed. “Earlier” is not itself proof of a safer or better result. Consent discussions should cover the proposed procedure, alternatives appropriate to the child, uncertainties and risks. This review does not independently rank techniques, dressings, patches or hospitals. Do not treat the older hospital leaflet’s blanket statement that there are no alternatives as an individual contemporary choice rule.
Breathing support, nutrition and feeding milestones
GOSH’s dated leaflet describes possible breathing support, temporary intravenous nutrition and a gradual transition to milk when tolerated. These are selected care descriptions, not a timetable. GOSH breathing and nutrition context.
Ask which support the baby currently needs and what must be reassessed before the next step. Separate abdominal-wall progress from respiratory and feeding progress: a completed operation is not a personal feeding instruction. If expressed milk is being collected, obtain the service’s actual storage and handling instructions. Do not change the nutritional route, dilute formula, increase feeds or add a thickener from a general online schedule. Request dietetic and equipment training for the plan that will apply at discharge. A marketed probiotic or “gut healing” preparation has not been independently shown in this review to replace congenital-defect repair, respiratory support or prescribed nutrition.
Recovery, later hernia and new symptoms
The older GOSH source notes that hernias can develop after repair and advises discussing a new abdominal bulge with a doctor. Cleveland Clinic flags wound drainage or redness, fever and especially green vomiting after surgery. GOSH selected follow-up; Cleveland Clinic postoperative warnings.
Ask the surgical team what remains planned and obtain the operative summary. That record can explain whether a later abdominal-wall procedure is expected, rather than making a family infer it from appearance. New symptoms need their own assessment. An apparently healed skin surface does not provide a complete account of the bowel or underlying wall. Describe the change, the previous repair and any feeding tube or intravenous line when contacting care. Do not use another child’s recovery story or a general success percentage to decide how long to wait at home. Follow-up should explain the purpose of each visit and how unanswered concerns will be reviewed.
Urgent illness and dehydration warnings
Breathing difficulty, blue or grey colour, collapse or difficulty waking a child requires emergency help. In the UK use 999 or emergency care; elsewhere use the local emergency route. NHS emergency signs.
Reduced urine or fewer wet nappies and unusual drowsiness can indicate dehydration requiring urgent assessment. NHS dehydration warning.
Use the surgical discharge contact for concerns, but do not wait for a routine callback when the child is seriously unwell. Tell emergency clinicians about the congenital defect, operations, current nutritional route and any equipment. A child does not need every warning sign before assessment is warranted. This guide gives no home fluid volume, tube intervention or line-care procedure. Seek the team’s actual instructions for an equipment problem rather than improvising a repair.
Medicines, supplements and research limits
Keep medicines, feeds and nonprescription products in the care record. NCCIH’s dated precautions support disclosing supplements before procedures or treatment changes. NCCIH product precautions.
Ask who reviews medicine administration if the nutritional route changes and what to do if a prescribed dose cannot be given as instructed. Do not crush, mix, stop or substitute a prescription independently. A deficiency assessment and an advertised product claim are separate issues. No supplement efficacy verdict for exomphalos is established here.
Animal or cell experiments are not used as proof of human benefit. A comparative repair claim would require the original human study, matched anatomy and associated conditions, patient-important outcomes, follow-up, funders and investigator interests. Government or hospital education does not itself clear those underlying financial chains. This guide therefore describes clinical decisions without a numerical benefit ranking or a personal procedure recommendation.
Funding and source roles
Research funding at a glance
17 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
National NHS England guidance, its genomics programme and provider explanations have distinct roles. Current accounts identify institutional routes; they do not identify a disease-page sponsor or clear its contributors and supporting studies. The GOSH leaflet is dated August 2016 with its review deadline passed. Source-specific gaps remain explicit, and no commercial efficacy source supports an independent treatment verdict.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS England exomphalos parent guide, posted July 2026 | Separate NHS England accounts. Exact contributor/page and source-study finance unclosed. | United Kingdom; NHS England national screening/education. | Tier 2 public care context, provisional. | C provisional — public clinical accountability favors accuracy; simplified guidance, national priorities and contributor/trial gaps remain. |
| NHS England exomphalos update history, July 2026 | Separate NHS England accounts. Exact contributor/page and source-study finance unclosed. | United Kingdom; NHS England national screening/education. | Tier 2 public care context, provisional. | C provisional — public clinical accountability favors accuracy; simplified guidance, national priorities and contributor/trial gaps remain. |
| NHS England GeNotes exomphalos, March 2025 | Separate NHS England accounts. Fadipe, Breeze, Powell and Woods credited; personal/page and source-study financial chains unclosed. | United Kingdom; NHS England Genomics Education Programme. | Tier 2 clinical context, provisional. | C provisional — dated expert review supports accuracy; genetics/public-service priorities and unresolved contributor interests remain. |
| GOSH exomphalos, August 2016 | Separate publisher financial profile. Page, contributor and study allocations unclosed. | United Kingdom; Great Ormond Street Hospital, London, England. | Tier 2 care context, provisional. | C provisional — clinical accountability favors accuracy; service/reputation incentives and unclosed interests; review overdue remain. |
| Cleveland Clinic omphalocele | See separate audited accounts, advertising and editorial policy. Page/reviewer and source-study receipts unclosed. | United States; Cleveland, Ohio. | Tier 2 provider context, provisional. | C provisional — July 2024 clinical education; professional accountability, referral incentives and unclosed interests remain. |
| NHS fetal anomaly scan, October 2024 | Separate publisher financial profile. Page, contributor and study allocations unclosed. | United Kingdom; national NHS website, distinct from trusts. | Tier 2 care context, provisional. | C provisional — clinical accountability favors accuracy; service/reputation incentives and unclosed interests remain. |
| NHS serious childhood illness, August 2026 | Separate publisher financial profile. Page, contributor and study allocations unclosed. | United Kingdom; national NHS website, distinct from trusts. | Tier 2 care context, provisional. | C provisional — clinical accountability favors accuracy; service/reputation incentives and unclosed interests remain. |
| NHS dehydration, May 2026 | Separate publisher financial profile. Page, contributor and study allocations unclosed. | United Kingdom; national NHS website, distinct from trusts. | Tier 2 care context, provisional. | C provisional — clinical accountability favors accuracy; service/reputation incentives and unclosed interests remain. |
| NHS national content policy, October 2022 | DHSC funding and no advertising/corporate sponsorship stated in its own policy. Full current contributor, source-study and page receipts unclosed. | United Kingdom; national NHS website. | Tier 3 financial/editorial self-report. | B provisional — disclosed safeguards and accountability; review due October 2025 passed. This policy does not identify provider-trust receipts. |
| NHS England annual accounts, 2025–26 | DHSC grant-in-aid is principal support; services and other operating receipts recognized separately. Proposed integration is not treated as completed. Exact programme, page and contributor allocations unclosed. | United Kingdom; 7–8 Wellington Place, Leeds, England. | Tier 3 statutory institutional financial report. | B provisional — public reporting favors accuracy; budget/mission incentives remain. Actual printed pages 130–131 read; not provider-trust or trial clearance. |
| GOSH audited annual accounts, 2025–26 | NHS England/ICB and private/overseas care, research/training, charity contributions and other service income; commercial research described. Separate GOSH Charity not controlled or consolidated. | United Kingdom; Great Ormond Street, London, England. | Tier 3 institutional financial report. | B provisional — statutory reporting favors accuracy; service/budget interests remain. Notes 2.1–2.3, 3.1 and charity boundary read. No leaflet/reviewer/trial clearance. |
| NCCIH supplement precautions, January 2019 | Separate appropriations history and gift authority. Page/contributor and cited-study receipts unclosed. | United States; NIH/HHS, Bethesda, Maryland. | Tier 2 public safety context, provisional. | C provisional — scientific accountability favors accuracy; dated summary and unclosed trial finances do not establish condition-specific benefit. |
| NCCIH appropriations history through FY2024 | Historical congressional appropriations table. No current-year enacted amount, accepted donor ledger or condition-page allocation inferred. | United States; NIH/HHS federal budget jurisdiction. | Tier 3 institutional fiscal reporting. | B provisional — transparent dated table favors accuracy; budget/mission incentives and missing page/trial allocations remain. |
| NCCIH Gift Fund authority and contact | Permitted gifts to public research agency; authority is not proof of a named accepted donor or sponsored page. Full receipt allocation unclosed. | United States; 31 Center Drive, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B provisional — explicit process/contact supports accuracy; fundraising/mission interests and donor gaps remain. |
| Cleveland Clinic: original audited 2025/2024 accounts | Provider statutory report; externally audited by EY. Patient/payer revenue, advisory services, research grants, corporate/foundation/individual pledges and investments. | United States; Cleveland Clinic Health System, Cleveland, Ohio. | Tier 3 provider financial self-report with external audit. | B, provisional — issued 9 March 2026, complete 75-page original accessed and relevant notes read. Audit concerns the accounts, not this article or intervention trials. |
| Cleveland Clinic: advertising policy | Site accepts advertising/sponsor revenue; provider retains content/placement approval and states editorial separation. | United States; Cleveland, Ohio. | Tier 3 own commercial-policy disclosure. | B, provisional — policy itself read; January 2020 guidelines state they can change. Actual page advertiser amounts and compliance not independently audited. |
| Cleveland Clinic: editorial policy | Institutional writing and expert-review process; mixed provider funds above, no individual reviewer-payment ledger. | United States; Cleveland, Ohio. | Tier 3 own process disclosure. | B, provisional — actual policy describes professional writers and medical-expert review. Accuracy incentive is credible; an institutional perspective and unverified individual conflicts remain. |
Frequently asked questions
Are exomphalos and omphalocele different diseases? They are two names for the same condition. Ask the team to use the confirmed diagnosis consistently in the care record.
Does every case have a genetic syndrome? An association is not an individual diagnosis. Ask which findings and tests support the actual assessment.
Why might closure be delayed? Ask which pathway is planned, what it protects and which later procedure remains intended. Do not equate a delayed closure plan with absence of specialist care.
Can a normal-looking wound settle every concern? Bring new feeding, breathing, wound or abdominal symptoms to the team. The clinical record and current examination matter more than appearance alone.
Sources and funding notes
Actual dates checked: GeNotes 13 March 2025; GOSH 1 August 2016, review due August 2017; Cleveland 11 July 2024. GOV.UK records a March 2020 document revision, February 2025 lead change and 2026 accessibility/translations; these do not prove a new clinical review. Numerical thresholds, success and recurrence figures, causal parent-risk claims and universal delivery instructions are excluded. Credited GeNotes contributors have unresolved personal financial chains; no unrelated namesake record is assigned to them.
- NHS England exomphalos parent guide, posted July 2026 — Selected diagnosis and single, staged or delayed repair context.
- NHS England exomphalos update history, July 2026 — Clinical revision and later administrative updates distinguished.
- NHS England GeNotes exomphalos, March 2025 — Selected associated genetic conditions and diagnostic principles; no individual recurrence or delivery rule.
- GOSH exomphalos, August 2016 — Dated selected breathing, nutrition and later hernia context.
- Cleveland Clinic omphalocele — Selected sac anatomy, fetal heart assessment and postoperative warning signs.
- NHS fetal anomaly scan, October 2024 — Screening and referral, not exclusion of all abnormalities.
- NHS serious childhood illness, August 2026 — Emergency warning signs.
- NHS dehydration, May 2026 — Selected urgent dehydration signs; no fluid prescription.
- NHS national content policy, October 2022 — Dated national website provenance only.
- NHS England annual accounts, 2025–26 — Actual 194-page original fiscal/HQ trace only.
- GOSH audited annual accounts, 2025–26 — Actual 200-page original retained locally; selected income notes read after web PDF fetch failed.
- NCCIH supplement precautions, January 2019 — Generic interaction/product disclosure only.
- NCCIH appropriations history through FY2024 — Historical fiscal route only.
- NCCIH Gift Fund authority and contact — Gift authority and headquarters only.
- Cleveland Clinic: original audited 2025/2024 accounts — Actual audited 2025/2024 provider accounts; no clinical-page or intervention-trial allocation.
- Cleveland Clinic: advertising policy — January 2020 commercial policy only; page receipts and compliance unclosed.
- Cleveland Clinic: editorial policy — Writing/review process only; individual financial interests not cleared.
Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.